Oragenics Completes Approximately $16.5 Million Offering

Stock Information for Avid Bioservices Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avid Bioservices Inc.

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium
Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.